CCR5-Ig fusion protein (Rappaport)

N/A

Report date: 2025/03/19 09:01:28

Base Information

Drug NameCCR5-Ig fusion protein (Rappaport)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionC-C chemokine receptor type 5 antagonistsImmunoglobulin agonists
TargetsC-C chemokine receptor type 5Immunoglobulin
Therapy Area/IndicationsInflammationAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRappaport Family Institute for Research in the Medical Sciences
China Registration ClassN/A

Develop Information

Active CompaniesBioRap Technologies LtdRappaport Family Institute for Research in the Medical Sciences
Inactive CompaniesN/A
Active IndicationsInflammationAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A